Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8237080 | 0.82 | MAPK13 (0.32) | CYP1A2CYP3A4NPSR1KDM4ELMNA | |
| SCHEMBL28221737 | 0.79 | KDM4E (0.37) | KDM4ELMNALRRK2ALDH1A1L3MBTL1 | |
| SCHEMBL8242647 | 0.77 | HTT (0.41) | HTTCYP1A2CYP3A4NPSR1KDM4E | |
| SCHEMBL13829723 | 0.77 | LRRK2 (0.50) | HTTCYP1A2CYP3A4NPSR1KDM4E | |
| SCHEMBL6719246 | 0.74 | PIK3CG (0.33) | KDM4ELRRK2ALDH1A1CDK2GAA | |
| SCHEMBL8237323 | 0.69 | KCNMA1 (0.33) | CYP3A4KDM4EALDH1A1HPGDGAA | |
| SCHEMBL12957026 | 0.69 | LRRK2 (0.43) | HTTKDM4ELRRK2CDK2 | |
| SCHEMBL8243678 | 0.69 | ALDH1A1 (0.41) | HTTCYP1A2CYP3A4KDM4ELMNA | |
| SCHEMBL8242638 | 0.68 | ALDH1A1 (0.53) | HTTCYP1A2CYP3A4NPSR1KDM4E | |
| SCHEMBL8237075 | 0.67 | MAPK8 (0.39) | KDM4EALDH1A1HPGDHSD17B10CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1966220-B1 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORP (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-1765829-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORP (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2007070393-A2 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | GRM1, GRM4, GRIA1 | HTT 374/4885CYP1A2 2877/4885CYP3A4 2775/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | HTT 374/4885CYP1A2 2877/4885CYP3A4 2775/4885 |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | GRM1, GRM4, GRIA1 | HTT 374/4885CYP1A2 2877/4885CYP3A4 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.